|
|
Home > Healthcare > Pharmaceutical > Generics
Generic Competition to 2009
|
| Published Date:
September 2005
Published By:
Urch Publishing
Page Count:
94
Order Code:
R410-123
|
|
|
|
“The period 2005 to 2009 will see the expiration of patent protection for 39 major drugs in the United States, an average of 8 a year. With 2004 seeing a decline in the number of NCEs approved down to 23 from 27 in 2003, there is clear evidence that the loss of revenue from patent protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market.”
Once patent protection and periods of marketing exclusivity expire for a branded drug, sales tend to decline dramatically as generic substitutes capture market share.
Patent expiration for a major product can see revenues for the supplier fall ten-fold within two years. The loss of patent protection for key products is increasingly significant in assessing the future performance of major pharmaceutical companies. The decline of revenues to generic substitutes has a major influence on the financial performance of such companies. Conversely, the successful identification and exploitation of the opportunities afforded by patent expirations provides a major growth driver for the pharmaceutical companies who focus their business on the provision of generic therapeutics.
With this background, Urch Publishing has commissioned a study into the effect of patent expiries on some of the major branded pharmaceutical products.
Generic Competition to 2009 provides the concise and accurate overview of forthcoming generic competition.
Key features of this report
- Reviews of over 40 major drugs that will come off patent btweeen 2005 and 2006
- Listing of generic regulatory filing activity
- Solid overview of market for generic drugs over the next four years
- Global product sales figures for years 2000-2004 with share by company revenue & market segment
Remember!
The increasing use of generic therapeutics, which combine high volumes with low prices, has led generics to capture 14% of the global healthcare market in 2004, with overall revenues of $58 billion. The imminent patent expirations of many major drugs, 42 in the period 2005 to 2009 in major markets, will provide a major growth stimulus for the generics companies as they compete to capture market share from multi-billion dollar drugs whose patents expire in this period.
You have been warned!
|
Similar Products
• Asia Pacific Pharma Sector Analysis
Published Nov 2009 by RNCOS
• Generic Pharmaceuticals Industry Report
Published Nov 2009 by Plimsoll Publishing Ltd.
• Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Antipsychotics Market Forecast
Published Oct 2009 by Datamonitor
• Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion
Published Oct 2009 by Datamonitor
• Generics: Global Industry Guide
Published Oct 2009 by Datamonitor
• Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential
Published Oct 2009 by Datamonitor
• Partnering in the Global Generics Industry 2008: A Guide to Companies
Published Oct 2009 by Espicom Healthcare Intelligence
• Cardiovascular Outlook: Pharmaceutical, Medical Device, New Technologies - Past, Present, and Future
Published Oct 2009 by Canon Communications, LLC
• China Hospital Drug Utilization Volume Executive Summary 2nd Edition 2009
Published Oct 2009 by Draco Healthcare Consulting LLC
|
|
|
|
0 items
